31.52 USD
↘ 1.15 (3.52%)AT CLOSE (11:59 AM EDT)
NewAmsterdam Pharma Company N.V. Ordinary Shares
NAMSNASDAQ • USD
32.46
↗ 0.94 (2.98%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
32.46
↗ 0.94 (2.98%)
Market: CLOSED
Open?$32.40
High?$33.26
Low?$30.90
Prev. Close?$32.67
Volume?1.1M
Avg. Volume?1.6M
VWAP?$31.68
Rel. Volume?0.71x
Bid / Ask
Bid?$26.58 × 100
Ask?$37.51 × 100
Spread?$10.93
Midpoint?$32.05
Valuation & Ratios
Market Cap?3.7B
Shares Out?116.9M
Float?62.2M
Float %?53.2%
P/E Ratio?N/A
P/B Ratio?5.39
EPS?-$1.74
Dividend?0.00%
Ex-Dividend?N/A
Shares of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) are trading at $31.52. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, NAMS is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Employees
100
Market Cap
3.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2022-11-23
Address
GOOIMEER 2-35
NARRDEN, P7 1411 DC
Phone: 35 206 2971
NARRDEN, P7 1411 DC
Phone: 35 206 2971
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?100
Momentum?10
Short Sent.?65
Piotroski F-Score?1/9Weak
Altman Z-Score?24.34Safe
Confidence?55%Low
Short InterestHigh
Short % of Float?11.47%High
Short Interest?7.1M
Days to Cover?3.7
Free Float62.2M
Avg Daily Volume1.9M
Settlement Date2026-05-15
Financial Health
Current Ratio?7.86Strong
Quick Ratio?7.86Strong
Cash Ratio?5.71Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?5.39FAIR▾
Peers100
S&P34
P/S?163.75HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-14.2CHEAP▾
S&P97
EV/Sales?141.97HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-29.8%WEAK▾
S&P6
ROA?-26.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-148029000
Enterprise Value?$3.2B
Fundamentals ratios updated end of day